Humanigen

Humanigen Debt

Delisted

Debt of Humanigen (HGENQ) as of Oct 5, 2026.

Debt

0.00USD

Last updated:

In 2026, Humanigen's total debt was 0.00 USD, a % change from the 25.01 M USD total debt recorded in the previous year.

The Humanigen Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2015
0.00 USD
Jan 1, 2016
4.29 M USD
Jan 1, 2017
19.37 M USD
Jan 1, 2018
3.50 M USD
Jan 1, 2019
6.49 M USD
Jan 1, 2020
0.00 USD
Jan 1, 2021
25.01 M USD
Jan 1, 2022
0.00 USD
The Humanigen Debt history
YEARDebtYoY
0.00USD-100.00%
25.01 MUSD—
0.00USD-100.00%
6.49 MUSD+85.43%
3.50 MUSD-81.93%
19.37 MUSD+351.52%
4.29 MUSD—
0.00USD-100.00%
10.93 MUSD—
Access this data via the Eulerpool API

Humanigen Stock analysis

What does Humanigen do? Humanigen Inc is a pharmaceutical company specializing in the discovery, development, and marketing of drugs, therapies, and solutions in the field of medical research. The company was originally founded in 2000 and is headquartered in Burlingame, California. One major focus of Humanigen Inc is the treatment of severe and life-threatening diseases such as cancer or HIV/AIDS that have not been sufficiently addressed by other medications. The company has developed a range of special technologies that enable it to develop innovative and effective therapies and drugs. An important aspect of Humanigen Inc's business model is collaboration with other companies, institutions, and research facilities worldwide. Through partnerships and cooperation, the company is able to cover the entire spectrum of research and development, allowing it to develop treatment options even faster and more effectively. Humanigen Inc has several different divisions and products designed for various applications. An important subsidiary of the company is the Humanigen Center for HIV Cure Research, which specifically focuses on combating HIV. There, the company works closely with scientists, researchers, and partners to develop new and innovative treatment options. Another important product of Humanigen Inc is the drug Lenzilumab. Lenzilumab is an antibody used to treat severe and life-threatening diseases such as cancer and COVID-19. Lenzilumab has shown great promise in clinical trials and could be the key to developing new and effective treatment options. In addition, Humanigen Inc has filed a variety of patents that enable it to develop new and innovative technologies in medical research. Many of these technologies are also licensed by other companies and research institutions, promoting the growth and expansion of Humanigen Inc. In recent years, the company has also placed a major focus on the field of digital technology. By utilizing big data, artificial intelligence, and other digital technologies, Humanigen Inc is able to develop new therapy options even faster and more effectively, catering specifically to the needs of patients and doctors. Overall, Humanigen Inc is an innovative and rapidly growing company focused on the development of new and effective treatment options for serious diseases. Through collaboration with other companies and institutions, the development of new technologies, and a targeted focus on the needs of patients and doctors, the company is able to respond even faster and more effectively to challenges in the field of medical research. Humanigen is one of the most popular companies on Eulerpool.

Debt Details

Understanding Humanigen's Debt Structure

Humanigen's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Humanigen's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Humanigen’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Humanigen’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Humanigen stock

On Eulerpool you can find the complete historical development of Debt Humanigen since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Humanigen historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Humanigen

All Key Metrics — Humanigen